Patent · US Active

RNA-editing oligonucleotides and uses thereof

US11453878B2 · kind B2 · utility

3Cited by
4References
18Claims
0Family size

Assignee

Inventors

Key dates

Filing dateJan 22, 2020
Grant dateSep 27, 2022
Priority date
Expiry dateNov 16, 2040

Classification

  • Technology area (CPC C)Chemistry; Metallurgy
  • CPC primaryC12N2310/351
  • WIPO fieldBiotechnology
  • WIPO sectorChemistry

Abstract

The present disclosure features useful compositions and methods to treat disorders for which deamination of an adenosine in an mRNA produces a therapeutic result, e.g., in a subject in need thereof.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.